Fig. 3From: Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysisTornado diagram for one-way sensitivity analyses. (A) the Chinese payer’s perspective. (B) the US payer’s perspectivePD: progressive disease; PFS: progression-free survival; AEs: adverse events; ICER: incremental cost-effectiveness ratioBack to article page